{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:56:52Z","timestamp":1791921412035,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T00:00:00Z","timestamp":1486339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.biologicals.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T05:15:19Z","timestamp":1487135719000},"page":"124-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["G-protein based ELISA as a potency test for rabies vaccines"],"prefix":"10.1016","volume":"46","author":[{"given":"Martine","family":"Chabaud-Riou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Guinchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Claire","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Niogret-Siohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Manin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Guinet-Morlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2017.02.002_bib1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(04)15792-9","article-title":"Rabies and other lyssavirus diseases","volume":"363","author":"Warrell","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2017.02.002_bib2","series-title":"Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs","year":"2007"},{"key":"10.1016\/j.biologicals.2017.02.002_bib3","series-title":"Rabies vaccine for human use prepared in cell culture","year":"2015"},{"key":"10.1016\/j.biologicals.2017.02.002_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(88)90185-5","article-title":"NIH test, a problematic method for testing potency of inactivated rabies vaccine","volume":"6","author":"Barth","year":"1988","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2017.02.002_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.provac.2011.10.004","article-title":"Alternative methods and strategies to reduce, refine, and replace animal use for human vaccine post-licensing safety testing: state of the science and future directions","volume":"5","author":"Isbrucker","year":"2011","journal-title":"Proc Vaccinol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biologicals.2005.07.004","article-title":"A\u00a0simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture","volume":"34","author":"Nagarajan","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2017.02.002_bib7","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.vaccine.2013.10.019","article-title":"A\u00a0relevant in\u00a0vitro ELISA test in alternative to the in\u00a0vivo NIH test for human rabies vaccine batch release","volume":"31","author":"Gibert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2017.02.002_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1996.0012","article-title":"Use of ELISA for in\u00a0vitro potency test of rabies vaccines for animal use","volume":"24","author":"Gamoh","year":"1996","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2017.02.002_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1348-0421.1998.tb02270.x","article-title":"Antigenic and functional analyses of glycoprotein of rabies virus using monoclonal antibodies","volume":"42","author":"Luo","year":"1998","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4049\/jimmunol.110.1.269","article-title":"Antigenic properties of rabies virus components","volume":"110","author":"Wiktor","year":"1973","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0264-410X(85)90224-5","article-title":"Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies","volume":"3","author":"Perrin","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2017.02.002_bib12","first-page":"295","article-title":"Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay","volume":"13","author":"Lafon","year":"1985","journal-title":"J\u00a0Biol Stand"},{"key":"10.1016\/j.biologicals.2017.02.002_bib13","first-page":"249","article-title":"A\u00a0comparison of the Pasteur and Pitman-Moore strains of rabies virus for the production of rabies vaccine in human diploid cells","volume":"5","author":"Majer","year":"1977","journal-title":"J\u00a0Biol Stand"},{"issue":"3","key":"10.1016\/j.biologicals.2017.02.002_bib14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI114260","article-title":"Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies","volume":"84","author":"Schumacher","year":"1989","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.biologicals.2017.02.002_bib15","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1371\/journal.pntd.0000542","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.biologicals.2017.02.002_bib16","series-title":"Protein biotinylation. Current protocols in protein science\/editorial board","author":"Elia","year":"2010"},{"key":"10.1016\/j.biologicals.2017.02.002_bib17","unstructured":"Statistical analysis of results of biological assays and tests (parallel line analysis described in section 3.2). European pharmacopeia monograph 5.3 (01\/2008). in Section 3.22008."},{"key":"10.1016\/j.biologicals.2017.02.002_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JVI.73.1.225-233.1999","article-title":"Chimeric lyssavirus glycoproteins with increased immunological potential","volume":"73","author":"Jallet","year":"1999","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib19","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1128\/JVI.64.6.3087-3090.1990","article-title":"Biological characterization of human monoclonal antibodies to rabies virus","volume":"64","author":"Dietzschold","year":"1990","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib20","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in\u00a0vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib21","first-page":"329","article-title":"Study of rabies virus by differential scanning calorimetry","volume":"4","author":"Toinon","year":"2015","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.biologicals.2017.02.002_bib22","unstructured":"International conference on harmonisation of technical requirement for registration of Pharmaceuticals for human use. ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1). Available at: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf."},{"key":"10.1016\/j.biologicals.2017.02.002_bib23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2460\/ajvr.2003.64.491","article-title":"Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice","volume":"64","author":"Wunderli","year":"2003","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.biologicals.2017.02.002_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biologicals.2009.01.001","article-title":"The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines","volume":"37","author":"Kramer","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2017.02.002_bib25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0264-410X(91)90188-C","article-title":"The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines","volume":"9","author":"Wunderli","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2017.02.002_bib26","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/eji.200526134","article-title":"The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries","volume":"35","author":"Kramer","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1099\/0022-1317-70-2-291","article-title":"Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein","volume":"70","author":"Bunschoten","year":"1989","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.biologicals.2017.02.002_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0042-6822(83)90349-5","article-title":"Chemical and immunological analysis of the rabies soluble glycoprotein","volume":"124","author":"Dietzschold","year":"1983","journal-title":"Virology"},{"key":"10.1016\/j.biologicals.2017.02.002_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1590\/S0074-02762002000200022","article-title":"Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle","volume":"97","author":"Piza","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.biologicals.2017.02.002_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/viro.2001.1271","article-title":"Genetic constraints and the adaptive evolution of rabies virus in nature","volume":"292","author":"Holmes","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.biologicals.2017.02.002_bib31","first-page":"291","article-title":"Standardization of an enzyme immunoassay for the in\u00a0vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera","volume":"17","author":"Thraenhart","year":"1989","journal-title":"J\u00a0Biol Stand"},{"key":"10.1016\/j.biologicals.2017.02.002_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/1045-1056(90)90037-Z","article-title":"In\u00a0vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody","volume":"18","author":"Perrin","year":"1990","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2017.02.002_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0166-0934(95)01999-5","article-title":"Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing","volume":"58","author":"Rooijakkers","year":"1996","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.biologicals.2017.02.002_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biologicals.2012.07.005","article-title":"Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward","volume":"40","author":"Stokes","year":"2012","journal-title":"Biologicals"},{"issue":"6","key":"10.1016\/j.biologicals.2017.02.002_bib35","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.vaccine.2016.12.039","article-title":"Replacement of in\u00a0vivo human rabies vaccine potency testing by in\u00a0vitro glycoprotein quantification using ELISA - results of an international collaborative study","volume":"35","author":"Morgeaux","year":"2017","journal-title":"Vaccine"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105617300118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105617300118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T06:47:15Z","timestamp":1692686835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105617300118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":35,"alternative-id":["S1045105617300118"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2017.02.002","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"G-protein based ELISA as a potency test for rabies vaccines","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}]}}